154 related articles for article (PubMed ID: 21242967)
1. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.
Mazot P; Cazes A; Boutterin MC; Figueiredo A; Raynal V; Combaret V; Hallberg B; Palmer RH; Delattre O; Janoueix-Lerosey I; Vigny M
Oncogene; 2011 Apr; 30(17):2017-25. PubMed ID: 21242967
[TBL] [Abstract][Full Text] [Related]
2. Control of ALK (wild type and mutated forms) phosphorylation: specific role of the phosphatase PTP1B.
Boutterin MC; Mazot P; Faure C; Doly S; Gervasi N; Tremblay ML; Vigny M
Cell Signal; 2013 Jun; 25(6):1505-13. PubMed ID: 23499906
[TBL] [Abstract][Full Text] [Related]
3. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
Passoni L; Longo L; Collini P; Coluccia AM; Bozzi F; Podda M; Gregorio A; Gambini C; Garaventa A; Pistoia V; Del Grosso F; Tonini GP; Cheng M; Gambacorti-Passerini C; Anichini A; Fossati-Bellani F; Di Nicola M; Luksch R
Cancer Res; 2009 Sep; 69(18):7338-46. PubMed ID: 19723661
[TBL] [Abstract][Full Text] [Related]
4. Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment.
Mazot P; Cazes A; Dingli F; Degoutin J; Irinopoulou T; Boutterin MC; Lombard B; Loew D; Hallberg B; Palmer RH; Delattre O; Janoueix-Lerosey I; Vigny M
PLoS One; 2012; 7(3):e33581. PubMed ID: 22479414
[TBL] [Abstract][Full Text] [Related]
5. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
Okubo J; Takita J; Chen Y; Oki K; Nishimura R; Kato M; Sanada M; Hiwatari M; Hayashi Y; Igarashi T; Ogawa S
Oncogene; 2012 Nov; 31(44):4667-76. PubMed ID: 22249260
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
Kwon MJ; Choi YL; Sung KW; Kang SY; Park SM; Choi SY; Kim JS; Suh YL
Pathol Res Pract; 2011 Oct; 207(10):634-9. PubMed ID: 21940108
[TBL] [Abstract][Full Text] [Related]
7. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Janoueix-Lerosey I; Lequin D; Brugières L; Ribeiro A; de Pontual L; Combaret V; Raynal V; Puisieux A; Schleiermacher G; Pierron G; Valteau-Couanet D; Frebourg T; Michon J; Lyonnet S; Amiel J; Delattre O
Nature; 2008 Oct; 455(7215):967-70. PubMed ID: 18923523
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
9. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.
Ogura T; Hiyama E; Kamei N; Kamimatsuse A; Ueda Y; Ogura K
J Pediatr Surg; 2012 Oct; 47(10):1789-96. PubMed ID: 23084186
[TBL] [Abstract][Full Text] [Related]
10. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
Heukamp LC; Thor T; Schramm A; De Preter K; Kumps C; De Wilde B; Odersky A; Peifer M; Lindner S; Spruessel A; Pattyn F; Mestdagh P; Menten B; Kuhfittig-Kulle S; Künkele A; König K; Meder L; Chatterjee S; Ullrich RT; Schulte S; Vandesompele J; Speleman F; Büttner R; Eggert A; Schulte JH
Sci Transl Med; 2012 Jul; 4(141):141ra91. PubMed ID: 22764207
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic mutations of ALK in neuroblastoma.
Ogawa S; Takita J; Sanada M; Hayashi Y
Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
13. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
[TBL] [Abstract][Full Text] [Related]
14. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
Mathivet T; Mazot P; Vigny M
Cell Signal; 2007 Dec; 19(12):2434-43. PubMed ID: 17904822
[TBL] [Abstract][Full Text] [Related]
15. Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.
Jiang CH; Huang CX; Chen YJ; Chuang YC; Huang BY; Yang CN
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004444
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.
Mourali J; Bénard A; Lourenço FC; Monnet C; Greenland C; Moog-Lutz C; Racaud-Sultan C; Gonzalez-Dunia D; Vigny M; Mehlen P; Delsol G; Allouche M
Mol Cell Biol; 2006 Aug; 26(16):6209-22. PubMed ID: 16880530
[TBL] [Abstract][Full Text] [Related]
17. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.
Martinsson T; Eriksson T; Abrahamsson J; Caren H; Hansson M; Kogner P; Kamaraj S; Schönherr C; Weinmar J; Ruuth K; Palmer RH; Hallberg B
Cancer Res; 2011 Jan; 71(1):98-105. PubMed ID: 21059859
[TBL] [Abstract][Full Text] [Related]
18. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma.
Cazes A; Louis-Brennetot C; Mazot P; Dingli F; Lombard B; Boeva V; Daveau R; Cappo J; Combaret V; Schleiermacher G; Jouannet S; Ferrand S; Pierron G; Barillot E; Loew D; Vigny M; Delattre O; Janoueix-Lerosey I
Cancer Res; 2013 Jan; 73(1):195-204. PubMed ID: 23139213
[TBL] [Abstract][Full Text] [Related]
19. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.
Donella-Deana A; Marin O; Cesaro L; Gunby RH; Ferrarese A; Coluccia AM; Tartari CJ; Mologni L; Scapozza L; Gambacorti-Passerini C; Pinna LA
Biochemistry; 2005 Jun; 44(23):8533-42. PubMed ID: 15938644
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.
Del Grosso F; De Mariano M; Passoni L; Luksch R; Tonini GP; Longo L
BMC Cancer; 2011 Dec; 11():525. PubMed ID: 22192458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
